Published in Mol Ther on December 23, 2008
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep (2015) 1.01
API5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res (2014) 1.00
Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res (2010) 0.99
The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer (2015) 0.93
Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res (2012) 0.90
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol (2011) 0.89
Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer. Hum Pathol (2012) 0.89
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol (2013) 0.86
Strategies for enhancing vaccine-induced CTL antitumor immune responses. J Biomed Biotechnol (2012) 0.82
DNA microarray-based analysis of voluntary resistance wheel running reveals novel transcriptome leading robust hippocampal plasticity. Physiol Rep (2014) 0.81
Novel PI3K/Akt inhibitors screened by the cytoprotective function of human immunodeficiency virus type 1 Tat. PLoS One (2011) 0.81
The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget (2016) 0.79
Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes. Clin Cancer Res (2015) 0.78
Pleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer target. PLoS One (2012) 0.77
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis (2015) 0.77
Synaptonemal complex protein 3 is a prognostic marker in cervical cancer. PLoS One (2014) 0.77
A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment. Oncoimmunology (2012) 0.75
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release (2016) 0.75
API5 confers cancer stem cell-like properties through the FGF2-NANOG axis. Oncogenesis (2017) 0.75
API5 induces cisplatin resistance through FGFR signaling in human cancer cells. Exp Mol Med (2017) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem (1996) 6.35
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene (2005) 3.42
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat (2002) 2.95
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest (2001) 2.61
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J (2001) 2.55
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A (1995) 2.27
Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res (2001) 1.75
Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther (2000) 1.41
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem (2001) 1.30
Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer (2006) 1.28
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res (2007) 1.18
A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm (2007) 1.16
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res (2008) 1.01
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol (2012) 2.59
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Diagnostic ability of optical coherence tomography with a normative database to detect localized retinal nerve fiber layer defects. Ophthalmology (2005) 2.03
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res (2010) 1.75
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis (2008) 1.67
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Human papillomavirus-related carcinomas of the sinonasal tract. Am J Surg Pathol (2013) 1.63
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation (2004) 1.62
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol (2012) 1.58
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol (2010) 1.56
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol (2011) 1.54
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Insertion of the ProSeal laryngeal mask airway is more successful with the 90 degrees rotation technique. Can J Anaesth (2010) 1.46
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
The impact of molecular testing on the surgical management of patients with thyroid nodules. Ann Surg Oncol (2014) 1.43
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Varying DNA base-pair size in subangstrom increments: evidence for a loose, not large, active site in low-fidelity Dpo4 polymerase. Biochemistry (2006) 1.38
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
The delayed leaf senescence mutants of Arabidopsis, ore1, ore3, and ore9 are tolerant to oxidative stress. Plant Cell Physiol (2004) 1.33
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol (2012) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope (2009) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Management and outcome of bleeding pseudoaneurysm associated with chronic pancreatitis. BMC Gastroenterol (2006) 1.23
The RAV1 transcription factor positively regulates leaf senescence in Arabidopsis. J Exp Bot (2010) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn (2009) 1.19
Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother (2005) 1.19
Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract. Am J Surg Pathol (2013) 1.19
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm (2007) 1.16
A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int (2008) 1.16
HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol (2012) 1.14
Air pollution and symptoms of depression in elderly adults. Environ Health Perspect (2012) 1.13
Is TKA using patient-specific instruments comparable to conventional TKA? A randomized controlled study of one system. Clin Orthop Relat Res (2013) 1.13
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Prevention of traumatic brain injury-induced neuronal death by inhibition of NADPH oxidase activation. Brain Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12